CV6 Therapeutics is a pioneering, clinical-stage, biotechnology company headquartered in Northern Ireland. We are committed to transforming patient care by disrupting the largest cornerstone therapy markets in oncology and inflammatory diseases. Our goal is to make proven cornerstone medicines dramatically more effective — for millions of patients.

We have developed first-in-class medicines that address significant unmet medical needs. Driven by the profound impact of cancer and inflammatory conditions on patients and families, we are committed to addressing the most difficult medical challenges and delivering measurable improvements in patient outcomes. Through innovative science and a focus on targeted therapies, we are building a next-generation pipeline designed to enhance the effectiveness of cornerstone treatments — making a lasting difference for millions of patients worldwide.

Our lead oncology asset, CV6-168, is currently progressing through Phase 1a clinical trials, while our inflammation program, CV6-1271, is advancing toward clinical readiness for autoimmune conditions such as rheumatoid arthritis.

At CV6 Therapeutics, we are driven by science, guided by unmet needs, and dedicated to delivering better outcomes for patients worldwide.